A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen with Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared with a Standard 3-dose Regimen

Project: Other project

Project Details

StatusActive
Effective start/end date12/22/20 → 12/21/25

Funding

  • Merck Sharp & Dohme Corporation: $37,808.97